Published in Gene Therapy Weekly, March 11th, 2004
The company's actual net loss for the year, in conformity with generally accepted accounting principles (GAAP), was $185.3 million, or $1.44 per share. This compares to the pro forma net loss for 2002 of $173.3 million, or $1.35 per share. The increase in the net loss is primarily due to reduced net interest income partially offset by increased revenue.
The company's actual net loss for 2003 of $185.3 million, or $1.44 per share, compares to its...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.